208 related articles for article (PubMed ID: 28927777)
1. The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection.
Poston G; Adam R; Xu J; Byrne B; Esser R; Malik H; Wasan H; Xu J
Eur J Surg Oncol; 2017 Nov; 43(11):2001-2011. PubMed ID: 28927777
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.
Rouyer M; François E; Cunha AS; Monnereau A; Noize P; Robinson P; Droz-Perroteau C; Le Monies de Sagazan A; Jové J; Lassalle R; Moore N; Fourrier-Réglat A; Smith D;
Clin Colorectal Cancer; 2018 Jun; 17(2):129-139. PubMed ID: 29523416
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
[TBL] [Abstract][Full Text] [Related]
5. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
[TBL] [Abstract][Full Text] [Related]
6. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E
Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968
[TBL] [Abstract][Full Text] [Related]
7. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
Malik H; Khan AZ; Berry DP; Cameron IC; Pope I; Sherlock D; Helmy S; Byrne B; Thompson M; Pulfer A; Davidson B
Eur J Surg Oncol; 2015 Apr; 41(4):499-505. PubMed ID: 25703078
[TBL] [Abstract][Full Text] [Related]
8. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
9. [A case report of conversion therapy for initially unresectable colorectal cancer liver metastases after cetuximab as third-line treatment].
Hamamoto Y; Komaki T; Miyamoto J; Akutsu N; Warita E; Yamanaka Y; Kuroki Y; Shirakawa H; Ozawa H; Tomikawa M; Hishinuma S; Hoshi S; Igarashi S; Ozasa T; Sugano Y; Kotake K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):1017-9. PubMed ID: 21677499
[TBL] [Abstract][Full Text] [Related]
10. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: A systematic review.
Okuno M; Hatano E; Nishino H; Seo S; Taura K; Uemoto S
Eur J Surg Oncol; 2017 Jun; 43(6):1003-1012. PubMed ID: 27624917
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
Ychou M; Rivoire M; Thezenas S; Guimbaud R; Ghiringhelli F; Mercier-Blas A; Mineur L; Francois E; Khemissa F; Chauvenet M; Kianmanesh R; Fonck M; Houyau P; Aparicio T; Galais MP; Audemar F; Assenat E; Lopez-Crapez E; Jouffroy C; Adenis A; Adam R; Bouché O
Br J Cancer; 2022 May; 126(9):1264-1270. PubMed ID: 34992255
[TBL] [Abstract][Full Text] [Related]
12. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
Bolhuis K; Kos M; van Oijen MGH; Swijnenburg RJ; Punt CJA
Eur J Cancer; 2020 Dec; 141():225-238. PubMed ID: 33189037
[TBL] [Abstract][Full Text] [Related]
13. Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases.
Galizia G; De Vita F; Lieto E; Zamboli A; Morgillo F; Castellano P; Mabilia A; Auricchio A; Renda A; Ciardiello F; Orditura M
Oncol Rep; 2013 Dec; 30(6):2992-8. PubMed ID: 24126855
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.
Ychou M; Rivoire M; Thezenas S; Quenet F; Delpero JR; Rebischung C; Letoublon C; Guimbaud R; Francois E; Ducreux M; Desseigne F; Fabre JM; Assenat E
Ann Surg Oncol; 2013 Dec; 20(13):4289-97. PubMed ID: 23955585
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary approach of colorectal liver metastases.
Juez I; Rubio C; Figueras J
Clin Transl Oncol; 2011 Oct; 13(10):721-7. PubMed ID: 21975333
[TBL] [Abstract][Full Text] [Related]
16. Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials.
Nasti G; Ottaiano A; Berretta M; Delrio P; Izzo F; Cassata A; Romano C; Facchini G; Scala D; Mastro A; Romano G; Perri F; Iaffaioli RV
Cancer Chemother Pharmacol; 2010 Jul; 66(2):209-18. PubMed ID: 20333385
[TBL] [Abstract][Full Text] [Related]
17. The role of biological agents in the resection of colorectal liver metastases.
Nordlinger B; Adam R; Arnold D; Zalcberg JR; Gruenberger T
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):432-42. PubMed ID: 22794325
[TBL] [Abstract][Full Text] [Related]
18. Complete resection of unresectable liver metastases from colorectal cancer without deterioration of liver function after cetuximab and irinotecan: two case reports.
Karasaki T; Sano K; Takamoto T; Kinoshita H; Tateishi R; Takemura T; Makuuchi M
Hepatogastroenterology; 2010; 57(104):1526-8. PubMed ID: 21443115
[TBL] [Abstract][Full Text] [Related]
19. Updated options for liver-limited metastatic colorectal cancer.
Alberts SR
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S58-62. PubMed ID: 19064408
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier?
Gomez D; De Rosa A; Addison A; Brooks A; Malik HZ; Cameron IC
Int J Surg; 2013; 11(7):507-13. PubMed ID: 23660586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
